MK-677 vs Epitalon
Both MK-677 and Epitalon are used for anti-aging. Here's how their evidence, dosing, and regulatory status actually compare.
MK-677
Evidence B+Ibutamoren (MK-677)
An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.
View full MK-677 profile →Epitalon
Evidence C+Epitalon (Epithalon, AEDG)
A synthetic tetrapeptide that reportedly upregulates telomerase activity. Russian longevity studies suggest mortality reductions but Western RCTs are absent.
View full Epitalon profile →Side-by-Side
| Attribute | MK-677 | Epitalon |
|---|---|---|
| Evidence Grade | B+ | C+ |
| FDA Status | Not FDA-approved — investigational (orally active GH secretagogue) | Not FDA-approved — Russian-origin research peptide |
| Typical Dose | 10–25 mg orally, once daily | 5–10 mg daily for 10–20 days, cycled (subcutaneous) |
| Clinics Indexed | 165 | 47 |
| Categories | growth-hormone, anti-aging | anti-aging, longevity |
Key reported benefits — MK-677
- ✓Sustained GH/IGF-1 elevation
- ✓Sleep depth
- ✓Lean mass
- ✓Bone density
Key reported benefits — Epitalon
- ✓Telomerase upregulation (preclinical)
- ✓Sleep/circadian normalization
- ✓Anti-aging signals
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.